Jacob Hartman

Specialty / focus areas. Jacob E. ("Jake") Hartman is an associate at Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C. in Washington, D.C., where his tracked patent work centers on biopharmaceutical litigation. Both of his tracked appearances are in Regeneron Pharmaceuticals' Hatch-Waxman/BPCIA-style suits over Eylea (aflibercept) — Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al. and Regeneron Pharmaceuticals, Inc. v. Formycon AG — consolidated in the In re Aflibercept Patent Litigation MDL before Judge Kleeh in the Northern District of West Virginia. The matters involve biologics patent claims (VEGF trap compositions, glycosylation, obviousness-type double patenting) and nationwide biosimilar marketing, consistent with his scientific training (Duke B.S. 2006; Penn M.B.E. 2015). His broader firm work also includes complex antitrust litigation (Meta Platforms, Sutter Health), so his practice is not pharma-only, but his patent docket is squarely life-sciences.

Side preference. Hartman has worked exclusively on the plaintiff side in the tracked cases — 2 of 2 appearances representing patent owner/innovator Regeneron against biosimilar challengers. No defendant-side patent appearances are tracked.

Firm context. He is an associate at Kellogg Hansen, a D.C.-based appellate and complex-litigation boutique known for Supreme Court and Federal Circuit work; no prior firms were identified in reliable sources. He appeared pro hac vice for Regeneron in the district court and is on the briefing/appellate teams in the related Federal Circuit appeals (Nos. 24-2058, 24-2147, 24-2351), where the Federal Circuit affirmed the district court's preliminary-injunction rulings against biosimilar entrants Samsung Bioepis and Formycon, including on personal jurisdiction and obviousness-type double-patenting defenses. I could not verify any additional verdicts or settlements attributable to him specifically.

PTAB / IPR; bar / education. No evidence surfaced that Hartman appears regularly in IPR/PGR proceedings; his tracked work is district court and Federal Circuit litigation. Per Martindale, he holds a B.S. from Duke (2006), an M.B.E. from Penn's Perelman School of Medicine (2015), and a J.D. from University of Pennsylvania Law School (2015), and was admitted to the D.C. Bar in 2017 — the only bar admission I could reliably source.